LeukoSite LDP-03 Phase III trials for third-line use in leukemia to begin in 1998 -- IPO prospectus.

Executive Summary

LEUKOSITE LDP-03 U.S. PHASE III STUDY IN FLUDARABINE-RESISTANT LEUKEMIA will begin in 1998 and will enroll 50 to 100 previously- treated chronic lymphocytic leukemia patients, Cambridge, Mass.-based LeukoSite said in a prospectus for an initial public offering. The company believes that its humanized lymphocyte depleting monoclonal antibody LDP-03 "may be effective for symptomatic patients who have failed the current standard of care and second line therapies," the prospectus states. Fludarabine (Berlex' Fludara) is indicated for second line use after chlorambucil (Glaxo Wellcome's Leukeran). "Unlike fludarabine and other traditional cytotoxic chemotherapies used to treat lymphomas and leukemias, LDP-03 does not deplete leukocyte-generating hematopoetic stem cells," the prospectus says.